360° UPSC Mains Analysis

Under the Seventh Schedule of the Constitution of India, 'Drugs and poisons' falls under Entry 19 of the Concurrent List (List III), allowing both the Center and States to legislate on it. However, 'Public health and sanitation; hospitals and dispensaries' falls under Entry 6 of the State List (List II). This creates a cooperative federalism framework where the Central Government sets uniform national standards and restrictions on drugs (such as Section 26A notifications), while State drug controllers are responsible for local enforcement and licensing.

India, known as the 'Pharmacy of the World', exported pharmaceuticals worth $30.47 billion in 2024-25. Tightening domestic regulatory standards under Section 26A of the Drugs and Cosmetics Act, 1940, enhances the global credibility of Indian pharma exports, mitigating quality concerns in international markets. While immediate exports of these specific pediatric FDCs to certain developing nations may face regulatory scrutiny, the long-term impact on trade trust and brand equity is highly positive.

The restriction on these pediatric FDCs is expected to have a negligible direct impact on India's overall GDP, but it will positively influence long-term human capital formation by reducing childhood morbidity. By preventing adverse drug events, it helps lower the national Out-of-Pocket Expenditure (OOPE) on healthcare, which stood at 43.4% of total health expenditure in 2022-23 (as per National Health Accounts Estimates). This reduction in OOPE frees up household disposable income, indirectly supporting private final consumption expenditure (PFCE).

The secondary sector (pharmaceutical manufacturing) will face short-term compliance costs for re-labeling, packaging, and updating promotional literature for all formulations containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride. Major domestic pharmaceutical companies with pediatric portfolios may experience a temporary dip in sales volume for the under-four demographic. Conversely, the tertiary sector (healthcare services) will benefit from a reduction in pediatric emergency visits related to adverse drug reactions.

The regulation will cause minor supply chain disruptions for retail chemists and distributors who must manage existing inventory and ensure compliance with the new labeling mandates. However, it protects consumer livelihoods by preventing wage loss for parents who would otherwise take unpaid leave to care for hospitalized children. It also shifts consumer demand toward safer, single-ingredient pediatric alternatives, stabilizing overall retail pharmacy revenues.

The historical root of drug regulation in India lies in the colonial era, specifically the early 20th century when the country lacked statutory control over the quality of imported and manufactured medicines. In response to public concern over substandard and adulterated drugs, the colonial government appointed the Drugs Enquiry Committee (Chopra Committee) in 1930 under Colonel R.N. Chopra. The committee's landmark 1931 report highlighted the absence of legislative control and recommended a centralized regulatory framework. This eventually led to the enactment of the Drugs and Cosmetics Act, 1940, which remains the bedrock of India's pharmaceutical regulation.

Post-independence, India's drug policy evolved to address the proliferation of irrational Fixed Dose Combinations (FDCs) that posed public health risks. A major milestone was the insertion of Section 26A into the Drugs and Cosmetics Act, 1940, via an amendment in 1982, empowering the Central Government to prohibit or restrict harmful or irrational drugs. In 2014, the Ministry of Health and Family Welfare constituted the Prof. C.K. Kokate Committee to systematically review thousands of FDCs, leading to the banning of hundreds of irrational formulations. This regulatory momentum has continued with targeted restrictions on pediatric formulations to safeguard vulnerable age groups.

The regulation of pediatric FDCs in India parallels global regulatory actions, such as the US FDA's 2007–2008 advisories and subsequent restrictions warning against the use of over-the-counter cough and cold medicines in infants and young children due to safety concerns and lack of proven efficacy. It also mirrors the US Drug Efficacy Study Implementation (DESI) program initiated in the late 1960s, which systematically evaluated and removed thousands of ineffective pre-1962 drug formulations, including many FDCs, from the market.

The push for drug regulation was closely linked to the Swadeshi Movement during the Indian freedom struggle, where nationalist leaders and scientists like Acharya Prafulla Chandra Ray advocated for indigenous pharmaceutical manufacturing and self-reliance. They protested against the dumping of substandard and adulterated foreign medicines into India, creating the political pressure that eventually forced the colonial government to establish the Chopra Committee in 1930.

The mandate directly protects the lives and bodily integrity of young children by preventing adverse drug reactions and toxicities associated with Chlorpheniramine Maleate and Phenylephrine Hydrochloride. However, it increases the daily caregiving burden and out-of-pocket expenditure for low-income parents, who must now seek formal medical consultations and purchase safer, potentially more expensive single-ingredient alternatives instead of relying on cheap OTC combinations.

The restriction aligns with Article 21 of the Constitution of India, which guarantees the Right to Life, judicially interpreted to include the right to health and safe medical treatment. It also fulfills the Directive Principle under Article 47, which mandates the State to regard the improvement of public health as among its primary duties. Internationally, it upholds Article 24 of the UN Convention on the Rights of the Child (UNCRC), which obligates states to ensure the highest attainable standard of health for children.

As a District Magistrate, the primary ethical conflict is Public Health Safety versus Healthcare Accessibility, where restricting popular, low-cost FDCs protects toddlers from clinical risks but may temporarily deprive impoverished families of immediate, affordable symptom relief. Additionally, there is a dilemma of Regulatory Enforcement versus Economic Livelihood, balancing the strict penalization of non-compliant local chemists under the Drugs and Cosmetics Act, 1940, against the survival of small-scale rural retail pharmacies.

This restriction primarily safeguards children under four years of age, particularly those from Economically Weaker Sections (EWS), rural, and tribal communities. These children are highly vulnerable to the risks of irrational Fixed Dose Combinations (FDCs) due to the prevalence of parental self-medication, low health literacy, and limited access to qualified pediatricians, which often leads to the administration of cheap, over-the-counter (OTC) drugs.